Odyssey Therapeutics Abandons Public Listing Amid US IPO Landscape Uncertainty
ByAinvest
Tuesday, Jun 10, 2025 1:04 pm ET1min read
OMEX--
The withdrawal is the latest indication that the IPO landscape may be suffering from economic uncertainty, particularly due to policies implemented by US President Donald Trump. In April, GlobalData business fundamentals analyst Alison Labya predicted that such policies could impact investor confidence and delay IPOs [1].
Biotech IPOs saw a strong recovery in 2024, with a total raise of $8.52 billion, up 68.4% from $5.06 billion raised in 2023. However, the uptick in 2025 has been tempered by market volatility and uncertainty, with Odyssey being the latest company to withdraw its IPO plans [1].
This move comes just months after Sionna Therapeutics successfully closed a nearly $220 million IPO, indicating that market conditions can vary significantly between companies. Telix Pharmaceuticals also withdrew its US public listing at the last minute in June 2024, citing unfavorable market conditions [1].
The IPO withdrawal by Odyssey Therapeutics underscores the importance of market timing and investor sentiment in the biotech sector. As the company stated in its notice to the SEC, it is "not in the best interests of the company to conduct the proposed offering at this time" [1].
References:
[1] https://www.pharmaceutical-technology.com/news/odyssey-bails-on-public-listing-as-us-ipo-landscape-stutters/
SION--
TLX--
Odyssey Therapeutics has withdrawn its registration statement for an initial public offering (IPO) due to unfavorable market conditions. The biotech company was eyeing an IPO to fund its pipeline, but the withdrawal is the first sign that the IPO landscape may be suffering from economic uncertainty caused by US President Donald Trump's policies.
Odyssey Therapeutics has withdrawn its registration statement for an initial public offering (IPO), citing unfavorable market conditions. The biotech company, which specializes in autoimmune and inflammatory diseases, was planning to list on the Nasdaq to fund its pipeline, including the Phase II trials for its RIPK2 inhibitor OD-07656 for ulcerative colitis treatment [1].The withdrawal is the latest indication that the IPO landscape may be suffering from economic uncertainty, particularly due to policies implemented by US President Donald Trump. In April, GlobalData business fundamentals analyst Alison Labya predicted that such policies could impact investor confidence and delay IPOs [1].
Biotech IPOs saw a strong recovery in 2024, with a total raise of $8.52 billion, up 68.4% from $5.06 billion raised in 2023. However, the uptick in 2025 has been tempered by market volatility and uncertainty, with Odyssey being the latest company to withdraw its IPO plans [1].
This move comes just months after Sionna Therapeutics successfully closed a nearly $220 million IPO, indicating that market conditions can vary significantly between companies. Telix Pharmaceuticals also withdrew its US public listing at the last minute in June 2024, citing unfavorable market conditions [1].
The IPO withdrawal by Odyssey Therapeutics underscores the importance of market timing and investor sentiment in the biotech sector. As the company stated in its notice to the SEC, it is "not in the best interests of the company to conduct the proposed offering at this time" [1].
References:
[1] https://www.pharmaceutical-technology.com/news/odyssey-bails-on-public-listing-as-us-ipo-landscape-stutters/
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet